Medical Device Manufacturer DME Kickbacks: Where the Usual Hospital Bundle Ends

Medical device manufacturer DME kickbacks can reach Medicare through a supplier’s claim when a manufacturer uses free services, equipment or other benefits to steer the supplier’s business. The manufacturer supplies the incentive. The supplier bills for the equipment. Unlike most hospital implants, durable medical equipment used at home can have a payment of its own. For someone in sales, patient outreach, reimbursement or supplier operations, the connection may be visible long before anyone reviewing a claim knows what to question.

How Does Reimbursement Work for Medical Devices?

Most implanted devices sit inside Medicare’s payment for a hospital procedure or stay. Durable medical equipment can be billed separately by the supplier under its own code. That difference changes where the sales decision meets the government bill.

The hospital outpatient payment rule generally packages implantable devices into the payment for the procedure. An inpatient hospital receives a payment for the stay that incorporates device costs. The supplier’s claim for a home ventilator follows a different path: the equipment itself generates a monthly rental bill.

Respiratory equipment, diabetic testing supplies and custom wheelchairs bring the supplier directly into the payment chain. Cardiac monitoring adds a service-company variation: the device records the patient’s heart activity, and the company bills for monitoring. The order, the patient’s eligibility, the service selected and continued equipment use each become potential points of comparison with the claim.

What the Manufacturer Can Give the Supplier

A manufacturer can buy a supplier’s attention with work the supplier would otherwise pay for. Respironics and ResMed settled allegations involving patient outreach, equipment, credit support and information useful for finding business.

Respironics and the Price of Using a Competitor’s Masks

Respironics agreed to a $34.8 million settlement in March 2016 over alleged kickbacks involving call-center services for suppliers of sleep-apnea masks. The call center helped meet patients’ resupply needs. According to the Justice Department, suppliers received the service free while their patients used Respironics masks. Patients using a competitor’s masks generated a monthly fee for the supplier.

That pricing rule gave the supplier a reason to favor the manufacturer’s product each time it handled resupplies. The alleged inducement was built into a service the supplier used to keep serving its existing patients. Under that pricing, the government said, suppliers whose patients used a competitor’s masks paid a monthly fee.

A later Respironics matter moved the benefit from patient outreach to sales information. In September 2022, Philips RS North America, formerly Respironics, agreed to pay over $24 million to resolve allegations that it gave suppliers physician prescribing data free of charge. Suppliers could use that information to market to physicians. The government alleged that the inducements caused supplier claims for ventilators, oxygen concentrators, CPAP and BiPAP machines, and other respiratory equipment paid for by Medicare, Medicaid and TRICARE.

The commercial advantage was access to information about who prescribed. The alleged false claims came afterward, when suppliers billed federal healthcare programs for the equipment.

ResMed’s Benefits Reached Suppliers, Sleep Labs and Physicians

ResMed’s January 2020 settlement of more than $37.5 million covered several ways a manufacturer could support the businesses that generated demand for its products. The Justice Department alleged that ResMed gave suppliers free call-center and patient-outreach services to facilitate resupply orders. It also allegedly gave sleep labs free or below-cost masks and diagnostic machines, along with free installation.

Credit support was another alleged benefit. The government alleged that ResMed arranged interest-free loans from third-party financial institutions for suppliers buying its equipment and committed to cover all payments due. The supplier obtained financing, and the manufacturer stood behind the debt.

The government also alleged that ResMed provided free ApneaLink home sleep-testing devices to physicians who were not sleep specialists. The allegations spanned the places where sleep-related care could begin, be tested and generate equipment orders. An employee who handled installation or financing might have seen a different part of the arrangement from someone who handled patient calls. Each could explain a benefit that a claims reviewer would never see on the bill itself.

Coloplast’s Alleged Patient-Switching Payments

The alleged incentive could also be a payment for moving patients to the manufacturer’s products. Coloplast and supplier Liberator Medical settled kickback allegations in December 2015. The government alleged payments to suppliers for promotions that switched individual users to Coloplast products. Both the manufacturer and a supplier were defendants in that case.

How a Supplier Benefit Reaches a False Claim

A manufacturer’s kickback can cause a false claim when it steers a supplier’s purchasing or referral decision and the supplier bills a federal health program for the resulting equipment. In the respiratory cases, the government alleged that manufacturers caused claims submitted by suppliers. In other cases, the supplier’s own intake, evaluation or billing policy supplied the false information.

The 2020 paper A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting, explains how a bill can mislead the government about what was supplied or whether the conditions for payment were met. That distinction helps explain why these cases require more than a review of the equipment invoice.

Respironics’ supplier-service terms explain the alleged inducement. The supplier’s resupply orders and claims show where that arrangement reached federal payment. At CardioNet, the comparison concerns the patient’s condition, the service billed and the diagnosis used to support it. At Numotion, it concerns who actually wrote the evaluation or what the supplier actually paid. The same general question leads into very different business records.

Supplier Claims Can Turn on Different Decisions

The same payment chain also exposes decisions made inside the supplier. Arriva’s case reached its manufacturer parent, Alere, through alleged approval of the supplier’s practices. At Numotion, CardioNet and Lincare, the conduct below concerned the supplier’s own evaluations, cost disclosures, service codes or rentals. The DME roadmap covers these supplier cases in detail.

Arriva’s Free Meters Reached Medicare Anyway

Arriva Medical and its parent, medical device company Alere, agreed to a $160 million settlement in August 2021 over allegations involving beneficiary kickbacks, ineligible meter claims and claims for deceased patients. The government alleged that Arriva offered free meters, billed Medicare without regard to eligibility and routinely waived copayments, with Alere’s approval. That parent-company approval differs from a manufacturer offering benefits to a supplier customer.

Numotion’s Evaluations and the Cost Behind the Invoice

Numotion’s wheelchair cases concerned the supplier’s own documentation. In an August 2024 settlement for $13.5 million, the government alleged that claims for custom wheelchairs and parts relied on patient evaluations unlawfully authored, completed or signed by Numotion employees instead of qualified medical professionals. A separate March 2023 settlement of $7 million concerned allegations that Numotion failed to disclose manufacturer discounts or its actual acquisition cost when billing Medicaid programs that based reimbursement on what it paid for manually priced equipment.

CardioNet’s More Expensive Monitoring Service

CardioNet’s service-coding case centered on allegedly billing a higher level of cardiac monitoring than patients needed. Its parent, BioTelemetry, agreed to a $6.4 million settlement in March 2015. The government alleged that CardioNet submitted the higher-level service code together with an inaccurate diagnosis code that misrepresented patients’ conditions.

In a separate case, AMI and Spectocor agreed to pay $9.56 million to resolve allegations that enrollment software steered Medicare and TRICARE patients into higher-cost PocketECG telemetry regardless of their medical condition.

Lincare Kept Billing After Patients Stopped Using Ventilators

Lincare admitted that it sometimes continued seeking monthly rental payments while knowing patients were not using their non-invasive ventilators. Its February 2024 civil settlement was $25.5 million. Lincare also admitted granting coinsurance waivers on some occasions to persuade patients to rent ventilators, without basing the waivers on financial need.

What Kind of Proof Is Needed to Be a Whistleblower?

The useful evidence connects a business decision to what a federal health program was asked to pay. A manufacturer employee may know the terms of a supplier benefit. A supplier employee may know how that benefit affected orders, or how an account continued generating claims after the reason for payment changed.

The cases put concrete records beside each other. Respironics’ call-center pricing and supplier orders explain the alleged incentive. Arriva’s intake promises, eligibility history and collection practices explain the alleged customer inducements and meter claims. Numotion’s evaluations show who supplied the assessment, while its acquisition-cost records explain what Medicaid was told about price. CardioNet’s service and diagnosis codes can be compared with the patient’s condition. Lincare’s visit records, use information and internal audits can be compared with monthly rentals.

In the respiratory settlements, the alleged benefits originated with the manufacturer and reached claims submitted by suppliers. In Numotion’s cases, the allegations concerned the supplier’s evaluations and cost disclosures. In Lincare’s case, the admissions concerned the supplier’s rental and coinsurance practices. We work with you to establish whose decisions drove the claims and where your knowledge fits.

Can a Whistleblower Take Legal Action Against a Medical Device Company?

Yes. A medical device manufacturer can face a False Claims Act case for knowingly causing false claims even when a supplier submits the bills. The Respironics and ResMed settlements show that connection in practice. A qui tam case allows a whistleblower to bring the government’s claim forward.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. ResMed’s settlement resolved five whistleblower cases, and the Justice Department announced a collective share of roughly $6.2 million. The Arriva case began with a former call-center employee. A Respironics employee brought the prescribing-data case, and the Justice Department announced that the employee would receive approximately $4.3 million of the federal settlement. Knowledge of the sales arrangement or the intake process can matter alongside knowledge of billing.

When You Know What Drove the Claim

If you recognize a supplier benefit, an evaluation written by the sales side or a rental that kept billing after use stopped, speak with our medical device fraud whistleblower experts. We turn your knowledge of those decisions into your strongest whistleblower case and bring in medical device and durable medical equipment whistleblower lawyers who understand the payment chain. We stay beside you from the first assessment through the decisions that shape your case.